Sendhil Mullainathan and Richard Thaler (M & T) address some interesting questions in their paper Behavioral Economics (September 2000). In doing so they justify the
I feel like I’m constantly defending myself for saying that the public option – or what’s left of it – just isn’t that valuable. I’m
In a prior post I suggested that about 3 million of the current 10 million Medicare Advantage (MA) enrollees might lose access to MA plans if
Medicare Advantage (MA) plans are a good deal for Medicare beneficiaries, though not for taxpayers. For the premium charged, they offer the most generous benefits
Although most of the world seems to have moved on from the screaming about mammograms last week, I can’t let it go. I really do
This post summarizes a 2008 article I coauthored with Steve Pizer and Ann Hendricks titled “Controlling Prescription Drug Costs: Regulation and the Role of Interest
